Loading clinical trials...
Loading clinical trials...
An Open-Label, Multicenter, Single-Arm, Phase II Study to Assess the Efficacy and Safety of Alectinib in Patients With ALK-Rearranged Non-Small Cell Lung Cancer After Disease Progression on Prior ALK Inhibitor Therapy
Conditions
Interventions
Alectinib
Locations
16
France
CHU Angers
Angers, France
Hopital Jean Minjoz; Pneumologie
Besançon, France
Hopital Augustin Morvan; Oncologie Thoracique
Brest, France
Centre Francois Baclesse; Comite 3
Caen, France
Centre Hospitalier Intercommunal; Service de Pneumologie
Créteil, France
Hôpital Nord Michallon; Pneumologie
La Tronche, France
Start Date
July 10, 2017
Primary Completion Date
September 26, 2019
Completion Date
September 26, 2019
Last Updated
February 10, 2020
NCT06667908
NCT04165798
NCT06875310
NCT07046923
NCT07222566
NCT06667076
Lead Sponsor
Hoffmann-La Roche
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions